IDH1 and central nervous system cancer: With respect to glioma, the functional illustration of (R)-enantiomer 2-hydroxygluterate (R-2-HG), produced through gain-of-function isocitrate dehydrogenase-1 (IDH1) mutations has fundamentally changed the way we approach these tumors [7, 8].